Prevail Therapeutics

OverviewSuggest Edit

Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.

TypePublic
Founded2017
HQNew York, US
Websiteprevailtherapeutics.com

Latest Updates

Employees (est.) (Sept 2019)48(+10%)
Job Openings8
Share Price (May 2020)$16.9 (-2%)

Key People/Management at Prevail Therapeutics

Asa Abeliovich

Asa Abeliovich

CEO & Founder, Director
Franz Hefti

Franz Hefti

Chief Development Officer
Yong Dai

Yong Dai

Chief Technology Officer
Jeffrey Sevigny

Jeffrey Sevigny

Chief Medical Officer
Brett Kaplan

Brett Kaplan

Chief Financial Officer
Emily Minkow

Emily Minkow

Chief Business Officer
Show more

Prevail Therapeutics Office Locations

Prevail Therapeutics has an office in New York
New York, US (HQ)
430 E 29th St #940
Show all (1)

Prevail Therapeutics Financials and Metrics

Prevail Therapeutics Revenue

USD

Net income (Q1, 2020)

(18.6m)

EBIT (Q1, 2020)

(19.3m)

Market capitalization (27-May-2020)

578.0m

Closing stock price (27-May-2020)

16.9

Cash (31-Mar-2020)

149.6m

EV

439.4m
Prevail Therapeutics's current market capitalization is $578 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

803.7k4.7m17.0m

R&D expense

995.4k14.1m48.8m

Operating expense total

1.8m18.8m65.8m

EBIT

(1.8m)(18.8m)(65.8m)
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

641.2k1.9m3.7m4.5m7.9m

R&D expense

1.3m8.4m12.0m16.8m11.4m

Operating expense total

1.9m10.3m15.7m21.3m19.3m

EBIT

(1.9m)(10.3m)(15.7m)(21.3m)(19.3m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

12.7m63.0m168.1m

Prepaid Expenses

104.7k562.7k6.4m

Current Assets

12.8m63.6m174.5m

PP&E

106.1k677.9k2.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

100.3m202.1m183.1m149.6m

Prepaid Expenses

4.4m4.3m7.4m4.9m

Current Assets

104.7m206.3m190.5m154.5m

PP&E

897.5k2.1m2.5m2.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(1.8m)(19.1m)(63.2m)

Depreciation and Amortization

2.0k54.9k265.0k

Accounts Payable

265.4k976.0k3.9m

Cash From Operating Activities

(987.3k)(14.0m)(55.8m)
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(3.2m)(9.9m)(25.0m)(45.3m)(18.6m)

Depreciation and Amortization

5.1k36.8k93.0k201.0k111.0k

Accounts Payable

459.7k713.2k762.0k3.7m(1.2m)

Cash From Operating Activities

(1.2m)(12.3m)(22.5m)(41.0m)(18.2m)
USDY, 2020

EV/EBIT

-22.8 x

EV/CFO

-24.1 x

Financial Leverage

1.1 x
Show all financial metrics

Prevail Therapeutics Online and Social Media Presence

Embed Graph

Prevail Therapeutics News and Updates

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations

Prevail Therapeutics to Present at Upcoming Conferences

NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that management will present at…

Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Adm…

Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations

Prevail Therapeutics Blogs

Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations

Company Will Present at Cowen Healthcare Conference Today NEW YORK , March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, provided an

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation Content Import Mon, 03/02/2020 - 07:01 Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment …

Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA

Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA Content Import Wed, 02/12/2020 - 07:01 Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA February 12, 2020 …

Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020

Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020 Content Import Thu, 02/06/2020 - 08:31 Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020 February 6, 2020 at 8:30 AM EST This release is a backfill from a News Wire …

Prevail Therapeutics Provides PR001 Program Update

Prevail Therapeutics Provides PR001 Program Update Content Import Thu, 01/09/2020 - 16:06 Prevail Therapeutics Provides PR001 Program Update January 9, 2020 at 4:05 PM EST This release is a backfill from a News Wire General PR001 Admi…

Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation

NEW YORK , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced today that the U.S.
Show more

Prevail Therapeutics Frequently Asked Questions

  • When was Prevail Therapeutics founded?

    Prevail Therapeutics was founded in 2017.

  • Who are Prevail Therapeutics key executives?

    Prevail Therapeutics's key executives are Asa Abeliovich, Franz Hefti and Yong Dai.

  • How many employees does Prevail Therapeutics have?

    Prevail Therapeutics has 48 employees.

  • Who are Prevail Therapeutics competitors?

    Competitors of Prevail Therapeutics include Brii Biosciences, Nordic Nanovector and Acousia Therapeutics.

  • Where is Prevail Therapeutics headquarters?

    Prevail Therapeutics headquarters is located at 430 E 29th St #940, New York.

  • Where are Prevail Therapeutics offices?

    Prevail Therapeutics has an office in New York.

  • How many offices does Prevail Therapeutics have?

    Prevail Therapeutics has 1 office.